Corvus Pharmaceuticals to Present at AACR Annual Meeting April 16 – 20 in New Orleans
Following are the specifics for Corvus' two poster presentations:
- Inhibition of Adenosine A2A Receptor (A2AR) by CPI-444 Enhances CD8+ T cell Killing of a HER-2/neu Expressing Murine Tumor
Authored by Blake A. Scott1, Todd Armstrong2, Elizabeth M. Jaffee2 |
Affiliations: 1Johns Hopkins University School of Medicine, Baltimore, MD; 2Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University School of Medicine, Baltimore |
Session Category: Experimental and Molecular Therapeutics |
Session Date/ Time: Sunday, Apr 17, 1:00 PM – 5:00 PM |
Location: Morial Convention Center, Halls G-J, Poster Section 17, Poster Board 1 |
- The Adenosine A2A Receptor Antagonist, CPI-444, Blocks Adenosine-Mediated T Cell Suppression and Exhibits Anti-Tumor Activity Alone and In Combination with Anti-PD-1 and Anti-PD-L1
Authored by Stephen Willingham1, Po Y. Ho1, Robert Leone2, Emily Piccione1, Carmen Choy1, Andrew Hotson1, Joseph Buggy1, Jonathan Powell2, Richard Miller1 |
Affiliations: 1Corvus Pharmaceuticals, Burlingame, Calif.; 2Sidney Kimmel Comprehensive Cancer Research Center, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore |
Session Category: Immunology |
Session Date/ Time: Monday, Apr 18, 1:00 PM – 5:00 PM |
Location: Morial Convention Center, Halls G-J, Poster Section 26, Poster Board 21 |
The following oral presentation will take place as follows:
- Adenosine A2a Receptor (A2aR) Antagonist as a Means of Enhancing the Efficacy of Checkpoint Blockade and Adoptive T Cell Therapy
Authored by Robert D. Leone, Judson M. Englert, Chih-Hsien Cheng, Jiayu Wen, Min-Hee Oh, Im-Hong Sun, Chirag Patel, Ian A. Bettencourt, Jonathan D. Powell |
Affiliation: Sidney Kimmel Comprehensive Cancer Research Center Johns Hopkins University School of Medicine, Baltimore |
Session Category: Immunology |
Session Date/ Time: Tuesday, Apr 19, 4:20 PM – 4:35 PM |
Location: Morial Convention Center, New Orleans Theater C |
To learn more about the Corvus pipeline visit http://www.corvuspharma.com/technology/.
ABOUT
INVESTOR CONTACT:Leiv Lea Chief Financial Officer LLea@corvuspharma.com 650-900-4522 MEDIA CONTACT:Julie Normart ,W2O Group 415-946-1087 jnormart@w2ogroup.com